Psoriasis

The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.

The study also found that over a decade, death rates did not change significantly for ankylosing spondylitis but decreased for inflammatory bowel disease (IBD).

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks on the positive safety and efficacy profile shown in the DERMIS-1 and DERMIS-2 trials exploring use of roflumilast cream in patients with chronic plaque psoriasis, including those with intertriginous disease.

Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.

A decade’s worth of retrospective data from over 1 million patients with end-stage renal disease (ESRD) undergoing dialysis showed that psoriasis may be protective against pneumonia in these patients.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA for the treatment of plaque psoriasis in patients aged 12 and older.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The findings add to previous research on similar outcomes between psoriasis and cardiovascular disease, using a Mendelian randomization study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.

The real-life findings showed that treatment with brodalumab improved health-related quality of life (HRQOL) for patients but itching prevented complete improvement.

Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks about disease manifestations, comorbidities, and other factors to consider in the management of psoriasis.

According to the investigator, these findings further support psoriasis as a systemic inflammatory disease.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.

Despite incidence of psoriasis decreasing, older populations in Taiwan have a higher risk of developing psoriasis and psoriatic arthritis, according to a recent study.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.

Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.

A Mendelian randomization study found that there appears to be a causal relationship between inflammatory bowel disease (IBD) and psoriasis.

Researchers found no evidence of increased risk for severe COVID-19 among children receiving biologic therapies for their psoriasis.

Patients with psoriatic arthritis (PsA) exhibited a higher prevalence of cardiovascular risk factors and events vs the general population, including atherothrombotic disease.

An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.

A systematic review found that skin clearance, symptom control, and treatment safety were among the highest expected outcomes of treatment for patients with psoriasis.

Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.

Efficacy of biologics was observed in both men and women with psoriasis, although female patients reported a greater impact from the disease on quality of life (QOL) and lower treatment satisfaction.